Abstract
HIV invades the CNS compartment very early in infection and infects monocytes, microglia, macrophages, and astrocytes. These cells comprise the CNS viral reservoir. Neuroinvasion can continue throughout the infected individual’s lifetime due to the migration of HIV-infected monocytes across the blood-brain barrier (BBB). Infection of the CNS stimulates the activation of both infected and uninfected cells, the production of neurotoxic viral proteins, the expression of chemokines which attract additional infected monocytes, and a persistent CNS inflammation that causes neuronal dysfunction and death. These events are responsible for the neurocognitive, motor, and behavioral deficits collectively known as HIV-associated neurocognitive disorder (HAND). Treatment with combined antiretroviral therapy (cART) reduces the pool of replicating virus and may also reduce inflammation; however, current cART cannot eradicate the CNS viral reservoir nor persistent CNS inflammation, as HIV has molecular mechanisms of evading the immune system and may also be protected from therapeutic levels of cART within the CNS. Thus, cART attenuates rather than cures the brain pathology underlying HAND. In addition, comorbid processes such as aging, cART neurotoxicity, drug use, HCV coinfection, and vascular risk factors may contribute to brain injury and exacerbate the manifestations of HAND.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
The Joint United Nations Programme on HIV/AIDS (UNAIDS) website [Internet], Geneva, Switzerland. The Joint United Nations Programme on HIV/AIDS. http://www.unaids.org/en/resources/fact-sheet. Accessed 25 Nov 2016
Centers for Disease Control and Prevention website [Internet], Atlanta, Georgia, GA. U.S. Department of Health & Human Services. Available from https://www.cdc.gov/hiv/basics/statistics.html. Accessed 15 Sept 2016
Bradley H et al (2014) Vital signs: HIV diagnosis, care, and treatment among persons living with HIV—United States, 2011. MMWR Morb Mortal Wkly Rep 63(47):1113–1117
Snider WD et al (1983) Neurological complications of acquired immune deficiency syndrome: analysis of 50 patients. Ann Neurol 14(4):403–418
Antinori A et al (2007) Updated research nosology for HIV-associated neurocognitive disorders. Neurology 69(18):1789–1799
Singh D (2012) What’s in a name? AIDS dementia complex, HIV-associated dementia, HIV-associated neurocognitive disorder or HIV encephalopathy. Afr J Psychiatry (Johannesbg) 15(3):172–175
Jordan BD et al (1985) Neurological syndromes complicating AIDS. Front Radiat Ther Oncol 19:82–87
McArthur JC et al (1993) Dementia in AIDS patients: incidence and risk factors. Multicenter AIDS cohort study. Neurology 43(11):2245–2252
Childs EA et al (1999) Plasma viral load and CD4 lymphocytes predict HIV-associated dementia and sensory neuropathy. Neurology 52(3):607–613
Stern Y et al (2001) Factors associated with incident human immunodeficiency virus-dementia. Arch Neurol 58(3):473–479
Epstein LG et al (1984) HTLV-III/LAV-like retrovirus particles in the brains of patients with AIDS encephalopathy. AIDS Res 1(6):447–454
Navia BA, Price RW (1987) The acquired immunodeficiency syndrome dementia complex as the presenting or sole manifestation of human immunodeficiency virus infection. Arch Neurol 44(1):65–69
Grant I et al (1987) Evidence for early central nervous system involvement in the acquired immunodeficiency syndrome (AIDS) and other human immunodeficiency virus (HIV) infections. Studies with neuropsychologic testing and magnetic resonance imaging. Ann Intern Med 107(6):828–836
Davis LE et al (1992) Early viral brain invasion in iatrogenic human immunodeficiency virus infection. Neurology 42(9):1736–1739
Singer EJ et al (1994) Intrathecal IgG synthesis and albumin leakage are increased in subjects with HIV-1 neurologic disease. J Acquir Immune Defic Syndr 7(3):265–271
Schmitt FA et al (1988) Neuropsychological outcome of zidovudine (AZT) treatment of patients with AIDS and AIDS-related complex. N Engl J Med 319(24):1573–1578
Sidtis JJ et al (1993) Zidovudine treatment of the AIDS dementia complex: results of a placebo-controlled trial. AIDS Clinical Trials Group. Ann Neurol 33(4):343–349
Kanyerere H et al (2015) Decline in adverse outcomes and death in tuberculosis patients in Malawi: association with HIV interventions. Public Health Action 5(2):116–118
Reniers G et al (2014) Mortality trends in the era of antiretroviral therapy: evidence from the network for analysing longitudinal population based HIV/AIDS data on Africa (ALPHA). AIDS 28(Suppl 4):S533–S542
Morris A et al (2011) An official ATS workshop report: emerging issues and current controversies in HIV-associated pulmonary diseases. Proc Am Thorac Soc 8(1):17–26
Evers S et al (2004) Prevention of AIDS dementia by HAART does not depend on cerebrospinal fluid drug penetrance. AIDS Res Hum Retrovir 20(5):483–491
Beguelin C et al (2014) Viral escape in the CNS with multidrug-resistant HIV-1. J Int AIDS Soc 17(4 Suppl 3):19745
Cysique LA, Brew BJ (2011) Prevalence of non-confounded HIV-associated neurocognitive impairment in the context of plasma HIV RNA suppression. J Neurovirol 17(2):176–183
Sacktor N et al (2001) HIV-associated neurologic disease incidence changes:: Multicenter AIDS Cohort Study, 1990–1998. Neurology 56(2):257–260
Joska JA et al (2010) Does highly active antiretroviral therapy improve neurocognitive function? A systematic review. J Neurovirol 16(2):101–114
McArthur JC et al (2004) Attenuated central nervous system infection in advanced HIV/AIDS with combination antiretroviral therapy. Arch Neurol 61(11):1687–1696
Gisslen M, Price RW, Nilsson S (2011) The definition of HIV-associated neurocognitive disorders: are we overestimating the real prevalence? BMC Infect Dis 11:356
Bearden DR, Meyer AC (2016) Should the Frascati criteria for HIV-associated neurocognitive disorders be used in children? Neurology 87(1):17–18
Cysique LA et al (2011) The burden of HIV-associated neurocognitive impairment in Australia and its estimates for the future. Sex Health 8(4):541–550
Pumpradit W et al (2010) Neurocognitive impairment and psychiatric comorbidity in well-controlled human immunodeficiency virus-infected Thais from the 2NN cohort study. J Neurovirol 16(1):76–82
Robertson KR et al (2007) The prevalence and incidence of neurocognitive impairment in the HAART era. AIDS 21(14):1915–1921
Heaton RK et al (2010) HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER study. Neurology 75(23):2087–2096
Harezlak J et al (2011) Persistence of HIV-associated cognitive impairment, inflammation, and neuronal injury in era of highly active antiretroviral treatment. AIDS 25(5):625–633
Gongvatana A et al (2013) Progressive cerebral injury in the setting of chronic HIV infection and antiretroviral therapy. J Neurovirol 19(3):209–218
Grant I et al (2014) Asymptomatic HIV-associated neurocognitive impairment increases risk for symptomatic decline. Neurology 82(23):2055–2062
Sacktor N et al (2016) Prevalence of HIV-associated neurocognitive disorders in the multicenter AIDS cohort study. Neurology 86(4):334–340
Marcotte TD et al (1999) The impact of HIV-related neuropsychological dysfunction on driving behavior. The HNRC group. J Int Neuropsychol Soc 5(7):579–592
Ellis RJ et al (1997) Neurocognitive impairment is an independent risk factor for death in HIV infection. San Diego HIV neurobehavioral research center group. Arch Neurol 54(4):416–424
Connors MH et al (2016) Mortality in mild cognitive impairment: a longitudinal study in memory clinics. J Alzheimers Dis 54(1):149–155
Wandeler G, Johnson LF, Egger M (2016) Trends in life expectancy of HIV-positive adults on antiretroviral therapy across the globe: comparisons with general population. Curr Opin HIV AIDS 11(5):492–500
Cherner M et al (2007) Neuropathologic confirmation of definitional criteria for human immunodeficiency virus-associated neurocognitive disorders. J Neurovirol 13(1):23–28
Cherner M et al (2002) Neurocognitive dysfunction predicts postmortem findings of HIV encephalitis. Neurology 59(10):1563–1567
Navia BA et al (1986) The AIDS dementia complex: II. Neuropathology. Ann Neurol 19(6):525–535
Gabuzda DH et al (1986) Immunohistochemical identification of HTLV-III antigen in brains of patients with AIDS. Ann Neurol 20(3):289–295
Wiley CA et al (1986) Cellular localization of human immunodeficiency virus infection within the brains of acquired immune deficiency syndrome patients. Proc Natl Acad Sci U S A 83(18):7089–7093
Churchill MJ et al (2006) Use of laser capture microdissection to detect integrated HIV-1 DNA in macrophages and astrocytes from autopsy brain tissues. J Neurovirol 12(2):146–152
Gray LR et al (2014) HIV-1 entry and trans-infection of astrocytes involves CD81 vesicles. PLoS One 9(2):e90620
Gray F et al (2000) Neuronal apoptosis in human immunodeficiency virus infection. J Neurovirol 6(Suppl 1):S38–S43
Glass JD et al (1993) Clinical-neuropathologic correlation in HIV-associated dementia. Neurology 43(11):2230–2237
Glass JD et al (1995) Immunocytochemical quantitation of human immunodeficiency virus in the brain: correlations with dementia. Ann Neurol 38(5):755–762
Kaul M (2009) HIV-1 associated dementia: update on pathological mechanisms and therapeutic approaches. Curr Opin Neurol 22(3):315–320
Everall I et al (2009) Cliniconeuropathologic correlates of human immunodeficiency virus in the era of antiretroviral therapy. J Neurovirol 15(5–6):360–370
Eden A et al (2007) Immune activation of the central nervous system is still present after >4 years of effective highly active antiretroviral therapy. J Infect Dis 196(12):1779–1783
Gannon P, Khan MZ, Kolson DL (2011) Current understanding of HIV-associated neurocognitive disorders pathogenesis. Curr Opin Neurol 24(3):275–283
Navia BA, Jordan BD, Price RW (1986) The AIDS dementia complex: I. Clinical features. Ann Neurol 19(6):517–524
Rohit M et al (2007) Education correction using years in school or reading grade-level equivalent? Comparing the accuracy of two methods in diagnosing HIV-associated neurocognitive impairment. J Int Neuropsychol Soc 13(3):462–470
Ryan EL et al (2005) Neuropsychological impairment in racial/ethnic minorities with HIV infection and low literacy levels: effects of education and reading level in participant characterization. J Int Neuropsychol Soc 11(7):889–898
Maki PM et al (2015) Cognitive function in women with HIV: findings from the Women’s interagency HIV study. Neurology 84(3):231–240
Heaps J et al (2013) Development of normative neuropsychological performance in Thailand for the assessment of HIV-associated neurocognitive disorders. J Clin Exp Neuropsychol 35(1):1–8
Robertson KR, Hall CD (2007) Assessment of neuroAIDS in the international setting. J Neuroimmune Pharmacol 2(1):105–111
Schouten J et al (2014) Cross-sectional comparison of the prevalence of age-associated comorbidities and their risk factors between HIV-infected and uninfected individuals: the AGEhIV cohort study. Clin Infect Dis 59(12):1787–1797
Fogel GB et al (2015) Factors related to HIV-associated neurocognitive impairment differ with age. J Neurovirol 21(1):56–65
Brew BJ et al (1992) Cerebrospinal fluid ([beta] 2-microglobulin in patients with AIDS dementia complex: an expanded series including response to zidovudine treatment. AIDS 6(5):461–466
Cohen RA et al (2010) Effects of nadir CD4 count and duration of human immunodeficiency virus infection on brain volumes in the highly active antiretroviral therapy era. J Neurovirol 16(1):25–32
Ellis RJ et al (2011) CD4 nadir is a predictor of HIV neurocognitive impairment in the era of combination antiretroviral therapy. AIDS 25(14):1747–1751
Hua X et al (2013) Disrupted cerebral metabolite levels and lower nadir CD4 + counts are linked to brain volume deficits in 210 HIV-infected patients on stable treatment. Neuroimage Clin 3:132–142
Tate DF et al (2011) Regional areas and widths of the midsagittal corpus callosum among HIV-infected patients on stable antiretroviral therapies. J Neurovirol 17(4):368–379
Valcour V et al (2012) Central nervous system viral invasion and inflammation during acute HIV infection. J Infect Dis 206(2):275–282
Hellmuth J et al (2016) Neurologic signs and symptoms frequently manifest in acute HIV infection. Neurology 87(2):148–154
Evering TH et al (2016) Rates of non-confounded HIV-associated neurocognitive disorders in men initiating combination antiretroviral therapy during primary infection. AIDS 30(2):203–210
Crum-Cianflone NF et al (2013) Low prevalence of neurocognitive impairment in early diagnosed and managed HIV-infected persons. Neurology 80(4):371–379
Ghate M et al (2015) The effects of antiretroviral treatment initiation on cognition in HIV-infected individuals with advanced disease in Pune, India. J Neurovirol 21(4):391–398
Joska JA et al (2012) Neuropsychological outcomes in adults commencing highly active anti-retroviral treatment in South Africa: a prospective study. BMC Infect Dis 12:39
Cysique LA, Maruff P, Brew BJ (2006) Variable benefit in neuropsychological function in HIV-infected HAART-treated patients. Neurology 66(9):1447–1450
Hartman TL, Buckheit RW Jr (2012) The continuing evolution of HIV-1 therapy: identification and development of novel antiretroviral agents targeting viral and cellular targets. Mol Biol Int 2012:401965
Saksena NK et al (2010) HIV reservoirs in vivo and new strategies for possible eradication of HIV from the reservoir sites. HIV AIDS (Auckl) 2:103–122
Kimata JT, Rice AP, Wang J (2016) Challenges and strategies for the eradication of the HIV reservoir. Curr Opin Immunol 42:65–70
Fletcher CV et al (2014) Persistent HIV-1 replication is associated with lower antiretroviral drug concentrations in lymphatic tissues. Proc Natl Acad Sci U S A 111(6):2307–2312
Franken L, Schiwon M, Kurts C (2016) Macrophages: sentinels and regulators of the immune system. Cell Microbiol 18(4):475–487
Kofler J, Wiley CA (2011) Microglia: key innate immune cells of the brain. Toxicol Pathol 39(1):103–114
Zhang YL et al (2015) Blood-brain barrier and neuro-AIDS. Eur Rev Med Pharmacol Sci 19(24):4927–4939
Chiodi F et al (1989) Biological characterization of paired human immunodeficiency virus type 1 isolates from blood and cerebrospinal fluid. Virology 173(1):178–187
Gras G, Kaul M (2010) Molecular mechanisms of neuroinvasion by monocytes-macrophages in HIV-1 infection. Retrovirology 7:30
Williams DW et al (2014) Monocytes mediate HIV neuropathogenesis: mechanisms that contribute to HIV associated neurocognitive disorders. Curr HIV Res 12(2):85–96
Brown A (2015) Understanding the MIND phenotype: macrophage/microglia inflammation in neurocognitive disorders related to human immunodeficiency virus infection. Clin Transl Med 4:7
Sonza S et al (2001) Monocytes harbour replication-competent, non-latent HIV-1 in patients on highly active antiretroviral therapy. AIDS 15(1):17–22
Kallianpur KJ et al (2012) Regional cortical thinning associated with detectable levels of HIV DNA. Cereb Cortex 22(9):2065–2075
Kusao I et al (2012) Cognitive performance related to HIV-1-infected monocytes. J Neuropsychiatry Clin Neurosci 24(1):71–80
Shiramizu B et al (2012) Failure to clear intra-monocyte HIV infection linked to persistent neuropsychological testing impairment after first-line combined antiretroviral therapy. J Neurovirol 18(1):69–73
Lassmann H et al (1993) Bone marrow derived elements and resident microglia in brain inflammation. Glia 7(1):19–24
Rappaport J, Volsky DJ (2015) Role of the macrophage in HIV-associated neurocognitive disorders and other comorbidities in patients on effective antiretroviral treatment. J Neurovirol 21(3):235–241
Honeycutt JB et al (2016) Macrophages sustain HIV replication in vivo independently of T cells. J Clin Invest 126(4):1353–1366
Cosenza MA et al (2002) Human brain parenchymal microglia express CD14 and CD45 and are productively infected by HIV-1 in HIV-1 encephalitis. Brain Pathol 12(4):442–455
Chugh P et al (2007) Infection of human immunodeficiency virus and intracellular viral tat protein exert a pro-survival effect in a human microglial cell line. J Mol Biol 366(1):67–81
Kaul M, Lipton SA (2006) Mechanisms of neuroimmunity and neurodegeneration associated with HIV-1 infection and AIDS. J Neuroimmune Pharmacol 1(2):138–151
Tan J, Sattentau QJ (2013) The HIV-1-containing macrophage compartment: a perfect cellular niche? Trends Microbiol 21(8):405–412
Gavegnano C et al (2013) Cellular pharmacology and potency of HIV-1 nucleoside analogs in primary human macrophages. Antimicrob Agents Chemother 57(3):1262–1269
Ene L, Duiculescu D, Ruta SM (2011) How much do antiretroviral drugs penetrate into the central nervous system? J Med Life 4(4):432–439
Komarova NL et al (2013) Relative contribution of free-virus and synaptic transmission to the spread of HIV-1 through target cell populations. Biol Lett 9(1):20121049
Ransom BR, Ransom CB (2012) Astrocytes: multitalented stars of the central nervous system. Methods Mol Biol 814:3–7
Cisneros IE, Ghorpade A (2012) HIV-1, methamphetamine and astrocyte glutamate regulation: combined excitotoxic implications for neuro-AIDS. Curr HIV Res 10(5):392–406
Eugenin EA, Berman JW (2007) Gap junctions mediate human immunodeficiency virus-bystander killing in astrocytes. J Neurosci 27(47):12844–12850
Eugenin EA et al (2011) Human immunodeficiency virus infection of human astrocytes disrupts blood-brain barrier integrity by a gap junction-dependent mechanism. J Neurosci 31(26):9456–9465
Ton H, Xiong H (2013) Astrocyte dysfunctions and HIV-1 neurotoxicity. J AIDS Clin Res 4(11):255
Churchill MJ et al (2009) Extensive astrocyte infection is prominent in human immunodeficiency virus-associated dementia. Ann Neurol 66(2):253–258
Li W et al (2011) IFN-gamma mediates enhancement of HIV replication in astrocytes by inducing an antagonist of the beta-catenin pathway (DKK1) in a STAT 3-dependent manner. J Immunol 186(12):6771–6778
Carroll-Anzinger D, Al-Harthi L (2006) Gamma interferon primes productive human immunodeficiency virus infection in astrocytes. J Virol 80(1):541–544
van Marle G et al (2004) Human immunodeficiency virus type 1 Nef protein mediates neural cell death: a neurotoxic role for IP-10. Virology 329(2):302–318
Schwartz L et al (2007) Evidence of human immunodeficiency virus type 1 infection of nestin-positive neural progenitors in archival pediatric brain tissue. J Neurovirol 13(3):274–283
Rothenaigner I et al (2007) Long-term HIV-1 infection of neural progenitor populations. AIDS 21(17):2271–2281
Lawrence DM et al (2004) Human immunodeficiency virus type 1 infection of human brain-derived progenitor cells. J Virol 78(14):7319–7328
Horsburgh A, Massoud TF (2013) The circumventricular organs of the brain: conspicuity on clinical 3T MRI and a review of functional anatomy. Surg Radiol Anat 35(4):343–349
Ragin AB et al (2006) Monocyte chemoattractant protein-1 correlates with subcortical brain injury in HIV infection. Neurology 66(8):1255–1257
McRae M (2016) HIV and viral protein effects on the blood brain barrier. Tissue Barriers 4(1):e1143543
Cunningham PH et al (2000) Evidence for independent development of resistance to HIV-1 reverse transcriptase inhibitors in the cerebrospinal fluid. AIDS 14(13):1949–1954
Smit TK et al (2004) Independent evolution of human immunodeficiency virus (HIV) drug resistance mutations in diverse areas of the brain in HIV-infected patients, with and without dementia, on antiretroviral treatment. J Virol 78(18):10133–10148
Bingham R et al (2011) HIV encephalitis despite suppressed viraemia: a case of compartmentalized viral escape. Int J STD AIDS 22(10):608–609
Ritola K et al (2005) Increased human immunodeficiency virus type 1 (HIV-1) env compartmentalization in the presence of HIV-1-associated dementia. J Virol 79(16):10830–10834
Dunfee RL et al (2006) The HIV Env variant N283 enhances macrophage tropism and is associated with brain infection and dementia. Proc Natl Acad Sci U S A 103(41):15160–15165
Imaz A et al (2014) Focal encephalitis related with viral escape and resistance emergence in cerebrospinal fluid in a patient on Lopinavir/ritonavir monotherapy with plasma HIV-1 RNA suppression. AIDS Res Hum Retrovir 30(10):984–987
Rawson T et al (2012) Factors associated with cerebrospinal fluid HIV RNA in HIV infected subjects undergoing lumbar puncture examination in a clinical setting. J Infect 65(3):239–245
Ferretti F et al (2014) Central nervous system HIV infection in “less-drug regimen” antiretroviral therapy simplification strategies. Semin Neurol 34(1):78–88
Bogoch II, Davis BT, Venna N (2011) Reversible dementia in a patient with central nervous system escape of human immunodeficiency virus. J Infect 63(3):236–239
Graham DR et al (2011) Initiation of HAART during acute simian immunodeficiency virus infection rapidly controls virus replication in the CNS by enhancing immune activity and preserving protective immune responses. J Neurovirol 17(1):120–130
Queen SE et al (2011) Replication-competent simian immunodeficiency virus (SIV) gag escape mutations archived in latent reservoirs during antiretroviral treatment of SIV-infected macaques. J Virol 85(17):9167–9175
Zink MC et al (2010) Simian immunodeficiency virus-infected macaques treated with highly active antiretroviral therapy have reduced central nervous system viral replication and inflammation but persistence of viral DNA. J Infect Dis 202(1):161–170
Koneru R, Olive MF, Tyor WR (2014) Combined antiretroviral therapy reduces brain viral load and pathological features of HIV encephalitis in a mouse model. J Neurovirol 20(1):9–17
Cook-Easterwood J et al (2007) Highly active antiretroviral therapy of cognitive dysfunction and neuronal abnormalities in SCID mice with HIV encephalitis. Exp Neurol 205(2):506–512
Lamers SL et al (2016) HIV DNA is frequently present within pathologic tissues evaluated at autopsy from cART-treated patients with undetectable viral load. J Virol 90(20):8968–8983
Letendre S et al (2008) Validation of the CNS penetration-effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol 65(1):65–70
Decloedt EH et al (2015) Central nervous system penetration of antiretroviral drugs: pharmacokinetic, pharmacodynamic and pharmacogenomic considerations. Clin Pharmacokinet 54(6):581–598
Smurzynski M et al (2011) Effects of central nervous system antiretroviral penetration on cognitive functioning in the ALLRT cohort. AIDS 25(3):357–365
Marra CM et al (2009) Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance. AIDS 23(11):1359–1366
Cross HM, Combrinck MI, Joska JA (2013) HIV-associated neurocognitive disorders: antiretroviral regimen, central nervous system penetration effectiveness, and cognitive outcomes. S Afr Med J = Suid-Afrikaanse tydskrif vir geneeskunde 103(10):758–762
Caniglia EC et al (2014) Antiretroviral penetration into the CNS and incidence of AIDS-defining neurologic conditions. Neurology 83(2):134–141
Ellis RJ et al (2014) Randomized trial of central nervous system-targeted antiretrovirals for HIV-associated neurocognitive disorder. Clin Infect Dis 58(7):1015–1022
Shikuma CM et al (2012) Antiretroviral monocyte efficacy score linked to cognitive impairment in HIV. Antivir Ther 17(7):1233–1242
Calcagno A, Di Perri G, Bonora S (2014) Pharmacokinetics and pharmacodynamics of antiretrovirals in the central nervous system. Clin Pharmacokinet 53(10):891–906
Stavros K, Simpson DM (2014) Understanding the etiology and management of HIV-associated peripheral neuropathy. Curr HIV/AIDS Rep 11(3):195–201
Huang W et al (2013) A clinically relevant rodent model of the HIV antiretroviral drug stavudine induced painful peripheral neuropathy. Pain 154(4):560–575
Dalakas MC, Semino-Mora C, Leon-Monzon M (2001) Mitochondrial alterations with mitochondrial DNA depletion in the nerves of AIDS patients with peripheral neuropathy induced by 2′3′-dideoxycytidine (ddC). Lab Investig 81(11):1537–1544
Pettersen JA et al (2006) Sensory neuropathy in human immunodeficiency virus/acquired immunodeficiency syndrome patients: protease inhibitor-mediated neurotoxicity. Ann Neurol 59(5):816–824
Robertson KR et al (2010) Neurocognitive effects of treatment interruption in stable HIV-positive patients in an observational cohort. Neurology 74(16):1260–1266
Shah A et al (2016) Neurotoxicity in the post-HAART era: caution for the antiretroviral therapeutics. Neurotox Res 30(4):677–697
Dellamonica P, Di Perri G, Garraffo R (2012) NNRTIs: pharmacological data. Med Mal Infect 42(7):287–295
Abers MS, Shandera WX, Kass JS (2014) Neurological and psychiatric adverse effects of antiretroviral drugs. CNS Drugs 28(2):131–145
Mollan KR et al (2014) Association between efavirenz as initial therapy for HIV-1 infection and increased risk for suicidal ideation or attempted or completed suicide: an analysis of trial data. Ann Intern Med 161(1):1–10
Funes HA et al (2014) Neuronal bioenergetics and acute mitochondrial dysfunction: a clue to understanding the central nervous system side effects of Efavirenz. J Infect Dis 210(9):1385–1395
Ciccarelli N et al (2011) Efavirenz associated with cognitive disorders in otherwise asymptomatic HIV-infected patients. Neurology 76(16):1403–1409
Tovar-y-Romo LB et al (2012) Dendritic spine injury induced by the 8-hydroxy metabolite of efavirenz. J Pharmacol Exp Ther 343(3):696–703
Rakhmanina NY, van den Anker JN (2010) Efavirenz in the therapy of HIV infection. Expert Opin Drug Metab Toxicol 6(1):95–103
Giunta B et al (2011) Antiretroviral medications disrupt microglial phagocytosis of beta-amyloid and increase its production by neurons: implications for HIV-associated neurocognitive disorders. Mol Brain 4(1):23
Brown LA et al (2014) Efavirenz promotes beta-secretase expression and increased Abeta1-40,42 via oxidative stress and reduced microglial phagocytosis: implications for HIV associated neurocognitive disorders (HAND). PLoS One 9(4):e95500
Paik IJ, Kotler DP (2011) The prevalence and pathogenesis of diabetes mellitus in treated HIV-infection. Best Pract Res Clin Endocrinol Metab 25(3):469–478
Calza L, Manfredi R, Chiodo F (2004) Dyslipidemia associated with antiretroviral therapy in HIV-infected patients. J Antimicrob Chemother 53(1):10–14
Zanni MV, Grinspoon SK (2012) HIV-specific immune dysregulation and atherosclerosis. Curr HIV/AIDS Rep 9(3):200–205
Becker JT et al (2009) Vascular risk factors, HIV serostatus, and cognitive dysfunction in gay and bisexual men. Neurology 73(16):1292–1299
Valcour VG et al (2005) Diabetes, insulin resistance, and dementia among HIV-1-infected patients. J Acquir Immune Defic Syndr 38(1):31–36
Robertson K, Liner J, Meeker RB (2012) Antiretroviral neurotoxicity. J Neurovirol 18(5):388–399
Azzam R et al (2006) Adverse effects of antiretroviral drugs on HIV-1-infected and -uninfected human monocyte-derived macrophages. J Acquir Immune Defic Syndr 42(1):19–28
Kaul M, Lipton SA (2006) Mechanisms of neuronal injury and death in HIV-1 associated dementia. Curr HIV Res 4(3):307–318
Maldarelli F et al (2007) ART suppresses plasma HIV-1 RNA to a stable set point predicted by pretherapy viremia. PLoS Pathog 3(4):e46
Vojnov L et al (2012) The majority of freshly sorted simian immunodeficiency virus (SIV)-specific CD8(+) T cells cannot suppress viral replication in SIV-infected macrophages. J Virol 86(8):4682–4687
Imamichi H et al (2016) Defective HIV-1 proviruses produce novel protein-coding RNA species in HIV-infected patients on combination antiretroviral therapy. Proc Natl Acad Sci U S A 113(31):8783–8788
Mocchetti I, Bachis A, Avdoshina V (2012) Neurotoxicity of human immunodeficiency virus-1: viral proteins and axonal transport. Neurotox Res 21(1):79–89
Kaul M, Garden GA, Lipton SA (2001) Pathways to neuronal injury and apoptosis in HIV-associated dementia. Nature 410(6831):988–994
Hu S et al (2009) Preferential sensitivity of human dopaminergic neurons to gp120-induced oxidative damage. J Neurovirol 15(5–6):401–410
Li W et al (2009) Role of tat protein in HIV neuropathogenesis. Neurotox Res 16(3):205–220
Chompre G et al (2013) Astrocytic expression of HIV-1 Nef impairs spatial and recognition memory. Neurobiol Dis 49:128–136
Jones GJ et al (2007) HIV-1 Vpr causes neuronal apoptosis and in vivo neurodegeneration. J Neurosci 27(14):3703–3711
Saito Y et al (1994) Overexpression of nef as a marker for restricted HIV-1 infection of astrocytes in postmortem pediatric central nervous tissues. Neurology 44(3 Pt 1):474–481
Hesselgesser J et al (1998) Neuronal apoptosis induced by HIV-1 gp120 and the chemokine SDF-1 alpha is mediated by the chemokine receptor CXCR4. Curr Biol 8(10):595–598
Bruce-Keller AJ et al (2003) Synaptic transport of human immunodeficiency virus-tat protein causes neurotoxicity and gliosis in rat brain. J Neurosci 23(23):8417–8422
Mediouni S et al (2012) Antiretroviral therapy does not block the secretion of the human immunodeficiency virus tat protein. Infect Disord Drug Targets 12(1):81–86
Wang T et al (2015) Intracellular Nef detected in peripheral blood mononuclear cells from HIV patients. AIDS Res Hum Retrovir 31(2):217–220
Yan YF et al (2011) HIV-1B gp120 genes from one patient with AIDS dementia complex can affect the secretion of tumor necrosis factor and interleukin 1beta in glial cells. Chin Med J 124(24):4217–4222
Ben Haij N et al (2015) HIV-1 tat protein induces production of Proinflammatory cytokines by human dendritic cells and monocytes/macrophages through engagement of TLR4-MD2-CD14 complex and activation of NF-kappaB pathway. PLoS One 10(6):e0129425
Lee JH et al (2016) HIV-Nef and ADAM17-containing plasma extracellular vesicles induce and correlate with immune pathogenesis in chronic HIV infection. EBioMedicine 6:103–113
Roesch F et al (2015) Vpr enhances tumor necrosis factor production by HIV-1-infected T cells. J Virol 89(23):12118–12130
Anzinger JJ et al (2014) Monocytes as regulators of inflammation and HIV-related comorbidities during cART. J Immunol Res 2014:569819
Hsu DC, Sereti I (2016) Serious non-AIDS events: therapeutic targets of immune activation and chronic inflammation in HIV infection. Drugs 76(5):533–549
Ghislain M et al (2015) Late antiretroviral therapy (ART) initiation is associated with long-term persistence of systemic inflammation and metabolic abnormalities. PLoS One 10(12):e0144317
Anthony IC et al (2005) Influence of HAART on HIV-related CNS disease and neuroinflammation. J Neuropathol Exp Neurol 64(6):529–536
Tavazzi E et al (2014) Brain inflammation is a common feature of HIV-infected patients without HIV encephalitis or productive brain infection. Curr HIV Res 12(2):97–110
Yuan L et al (2013) Cytokines in CSF correlate with HIV-associated neurocognitive disorders in the post-HAART era in China. J Neurovirol 19(2):144–149
Heyes MP et al (1991) Quinolinic acid in cerebrospinal fluid and serum in HIV-1 infection: relationship to clinical and neurological status. Ann Neurol 29(2):202–209
Kerr SJ et al (1998) Chronic exposure of human neurons to quinolinic acid results in neuronal changes consistent with AIDS dementia complex. AIDS 12(4):355–363
Gelbard HA et al (1994) Platelet-activating factor: a candidate human immunodeficiency virus type 1-induced neurotoxin. J Virol 68(7):4628–4635
Sei S et al (1995) Increased human immunodeficiency virus (HIV) type 1 DNA content and quinolinic acid concentration in brain tissues from patients with HIV encephalopathy. J Infect Dis 172(3):638–647
Kandanearatchi A, Brew BJ (2012) The kynurenine pathway and quinolinic acid: pivotal roles in HIV associated neurocognitive disorders. FEBS J 279(8):1366–1374
Valle M et al (2004) CSF quinolinic acid levels are determined by local HIV infection: cross-sectional analysis and modelling of dynamics following antiretroviral therapy. Brain 127(Pt 5):1047–1060
Drewes JL et al (2015) Quinolinic acid/tryptophan ratios predict neurological disease in SIV-infected macaques and remain elevated in the brain under cART. J Neurovirol 21(4):449–463
Chan DP et al (2016) Sexually acquired hepatitis C virus infection: a review. Int J Infect Dis 49:47–58
Rezaei N et al (2016) Risk factor analysis of hepatitis C virus seropositivity in Iranian blood donors: a case-control study. Transfusion 56(7):1891–1898
Operskalski EA, Kovacs A (2011) HIV/HCV co-infection: pathogenesis, clinical complications, treatment, and new therapeutic technologies. Curr HIV/AIDS Rep 8(1):12–22
Hilsabeck RC, Perry W, Hassanein TI (2002) Neuropsychological impairment in patients with chronic hepatitis C. Hepatology 35(2):440–446
Posada C et al (2010) Implications of hepatitis C virus infection for behavioral symptoms and activities of daily living. J Clin Exp Neuropsychol 32(6):637–644
Paulino AD et al (2011) Neurotoxic effects of the HCV core protein are mediated by sustained activation of ERK via TLR2 signaling. J Neurovirol 17(4):327–340
Gill AJ, Kolson DL (2014) Chronic inflammation and the role for cofactors (hepatitis C, drug abuse, antiretroviral drug toxicity, aging) in HAND persistence. Curr HIV/AIDS Rep 11(3):325–335
Mathew S et al (2016) Hepatitis C virus and neurological damage. World J Hepatol 8(12):545–556
Clifford DB et al (2015) Absence of neurocognitive effect of hepatitis C infection in HIV-coinfected people. Neurology 84(3):241–250
Fletcher NF et al (2010) Hepatitis C virus infection of neuroepithelioma cell lines. Gastroenterology 139(4):1365–1374
Wilkinson J, Radkowski M, Laskus T (2009) Hepatitis C virus neuroinvasion: identification of infected cells. J Virol 83(3):1312–1319
Pflugrad H et al (2016) Cerebral microglia activation in hepatitis C virus infection correlates to cognitive dysfunction. J Viral Hepat 23(5):348–357
Han ZQ et al (2015) Expression profile and kinetics of cytokines and chemokines in patients with chronic hepatitis C. Int J Clin Exp Med 8(10):17995–18003
Korolevskaya LB et al (2016) Systemic activation of the immune system in HIV infection: the role of the immune complexes (hypothesis). Med Hypotheses 88:53–56
Byrd DA et al (2013) Isolating cognitive and neurologic HIV effects in substance-dependent, confounded cohorts: a pilot study. J Int Neuropsychol Soc 19(4):463–473
Mahajan SD et al (2008) Tight junction regulation by morphine and HIV-1 tat modulates blood-brain barrier permeability. J Clin Immunol 28(5):528–541
Mahajan SD et al (2008) Methamphetamine alters blood brain barrier permeability via the modulation of tight junction expression: implication for HIV-1 neuropathogenesis in the context of drug abuse. Brain Res 1203:133–148
Dave RS (2012) Morphine affects HIV-induced inflammatory response without influencing viral replication in human monocyte-derived macrophages. FEMS Immunol Med Microbiol 64(2):228–236
Peterson PK et al (1990) Morphine promotes the growth of HIV-1 in human peripheral blood mononuclear cell cocultures. AIDS 4(9):869–873
Pitcher J et al (2010) Disruption of neuronal CXCR4 function by opioids: preliminary evidence of ferritin heavy chain as a potential etiological agent in neuroAIDS. J Neuroimmunol 224(1–2):66–71
El-Hage N et al (2006) HIV-1 tat and opiate-induced changes in astrocytes promote chemotaxis of microglia through the expression of MCP-1 and alternative chemokines. Glia 53(2):132–146
Bell JE et al (1998) HIV encephalitis, proviral load and dementia in drug users and homosexuals with AIDS. Effect of neocortical involvement. Brain 121(Pt 11):2043–2052
Sawaya BE et al (2009) TNF alpha production in morphine-treated human neural cells is NF-kappaB-dependent. J Neuroimmune Pharmacol 4(1):140–149
Bruce-Keller AJ et al (2008) Morphine causes rapid increases in glial activation and neuronal injury in the striatum of inducible HIV-1 tat transgenic mice. Glia 56(13):1414–1427
Fitting S et al (2010) Interactive comorbidity between opioid drug abuse and HIV-1 tat: chronic exposure augments spine loss and sublethal dendritic pathology in striatal neurons. Am J Pathol 177(3):1397–1410
Gurwell JA et al (2001) Synergistic neurotoxicity of opioids and human immunodeficiency virus-1 tat protein in striatal neurons in vitro. Neuroscience 102(3):555–563
Hauser KF et al (2012) Opiate drug use and the pathophysiology of neuroAIDS. Curr HIV Res 10(5):435–452
El-Hage N et al (2008) Morphine exacerbates HIV-1 tat-induced cytokine production in astrocytes through convergent effects on [ca(2+)](i), NF-kappaB trafficking and transcription. PLoS One 3(12):e4093
Cheng YC et al (2016) Cocaine use and risk of ischemic stroke in young adults. Stroke 47(4):918–922
Webber MP et al (1999) A prospective study of HIV disease progression in female and male drug users. AIDS 13(2):257–262
Fiala M et al (2005) Cocaine increases human immunodeficiency virus type 1 neuroinvasion through remodeling brain microvascular endothelial cells. J Neurovirol 11(3):281–291
Buch S et al (2012) Cocaine and HIV-1 interplay in CNS: cellular and molecular mechanisms. Curr HIV Res 10(5):425–428
Aksenov MY et al (2006) Cocaine-mediated enhancement of tat toxicity in rat hippocampal cell cultures: the role of oxidative stress and D1 dopamine receptor. Neurotoxicology 27(2):217–228
Araos P et al (2015) Plasma profile of pro-inflammatory cytokines and chemokines in cocaine users under outpatient treatment: influence of cocaine symptom severity and psychiatric co-morbidity. Addict Biol 20(4):756–772
Moratalla R et al (2015) Amphetamine-related drugs neurotoxicity in humans and in experimental animals: main mechanisms. Prog Neurobiol 155:149–170
Cherner M et al (2010) Methamphetamine use parameters do not predict neuropsychological impairment in currently abstinent dependent adults. Drug Alcohol Depend 106(2–3):154–163
Liu X et al (2012) Methamphetamine increases LPS-mediated expression of IL-8, TNF-alpha and IL-1beta in human macrophages through common signaling pathways. PLoS One 7(3):e33822
Carrico AW (2011) Substance use and HIV disease progression in the HAART era: implications for the primary prevention of HIV. Life Sci 88(21–22):940–947
Hoefer MM et al (2015) Combination of methamphetamine and HIV-1 gp120 causes distinct long-term alterations of behavior, gene expression, and injury in the central nervous system. Exp Neurol 263:221–234
Mediouni S et al (2015) The cross-talk of HIV-1 tat and methamphetamine in HIV-associated neurocognitive disorders. Front Microbiol 6:1164
Chana G et al (2006) Cognitive deficits and degeneration of interneurons in HIV+ methamphetamine users. Neurology 67(8):1486–1489
Quiros-Roldan E et al (2016) Incidence of cardiovascular events in HIV-positive patients compared to general population over the last decade: a population-based study from 2000 to 2012. AIDS Care 28(12):1551–1558
Thakur KT et al (2016) Stroke in HIV-infected African Americans: a retrospective cohort study. J Neurovirol 22(1):50–55
Webb MS et al (2007) Cigarette smoking among HIV+ men and women: examining health, substance use, and psychosocial correlates across the smoking spectrum. J Behav Med 30(5):371–383
Nou E, Lo J, Grinspoon SK (2016) Inflammation, immune activation, and cardiovascular disease in HIV. AIDS 30(10):1495–1509
Willig AL, Overton ET (2016) Metabolic complications and glucose metabolism in HIV infection: a review of the evidence. Curr HIV/AIDS Rep 13(5):289–296
Levitt NS et al (2016) Increased risk of dysglycaemia in South Africans with HIV; especially those on protease inhibitors. Diabetes Res Clin Pract 119:41–47
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer Science+Business Media LLC
About this chapter
Cite this chapter
Singer, E.J., Nemanim, N.M. (2017). The Persistence of HIV-Associated Neurocognitive Disorder (HAND) in the Era of Combined Antiretroviral Therapy (cART). In: Shapshak, P., et al. Global Virology II - HIV and NeuroAIDS. Springer, New York, NY. https://doi.org/10.1007/978-1-4939-7290-6_16
Download citation
DOI: https://doi.org/10.1007/978-1-4939-7290-6_16
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4939-7288-3
Online ISBN: 978-1-4939-7290-6
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)